Susquehanna International Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Susquehanna International Group’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-31,300	Closed	-$17K	–	11372
2019 Q4	$17K	Sell	31,300 -158,500	-84%	-$384K	﹤0.01%	9508
2019 Q3	$723K	Sell	189,800 -96,700	-34%	-$348K	﹤0.01%	6441
2019 Q2	$1.91M	Buy	286,500 +226,200	+375%	+$861K	﹤0.01%	4263
2019 Q1	$214K	Buy	+60,300	New	+$327K	﹤0.01%	7780
2018 Q4	–	Sell	-16,180	Closed	-$320K	–	10468
2018 Q3	$320K	Buy	16,180 +8,360	+107%	+$211K	﹤0.01%	7363
2018 Q2	$248K	Sell	7,820 -9,440	-55%	-$340K	﹤0.01%	8209
2018 Q1	$639K	Sell	17,260 -12,980	-43%	-$853K	﹤0.01%	6155
2017 Q4	$2.39M	Buy	+30,240	New	+$2.24M	﹤0.01%	3600

Susquehanna International Group's MLNT Position: Q3 2019 in Review

Susquehanna International Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 143,285 shares — an estimated $516K sold.

Susquehanna International Group first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $953K in Q2 2019. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

Susquehanna International Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Susquehanna International Group sold 143,285 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $516K.
Susquehanna International Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Susquehanna International Group's Melinta Therapeutics, Inc. Common Stock position peaked at $953K in Q2 2019.
47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.